Establishment and characterization of a triple negative basal‑like breast cancer cell line with multi‑drug resistance

Boichuk,Sergei; Galembikova,Aigul; Sitenkov,Alexandr; Khusnutdinov,Ramil; Dunaev,Pavel; Valeeva,Elena; Usolova,Natalia

doi:10.3892/ol.2017.6795

Establishment and characterization of a triple negative basal‑like breast cancer cell line with multi‑drug resistance

Authors:
- Sergei Boichuk
- Aigul Galembikova
- Alexandr Sitenkov
- Ramil Khusnutdinov
- Pavel Dunaev
- Elena Valeeva
- Natalia Usolova
View Affiliations

Affiliations: Department of Pathology, Kazan State Medical University, Kazan 420012, Russia
Published online on: August 23, 2017 https://doi.org/10.3892/ol.2017.6795
Pages: 5039-5045

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple‑negative breast carcinoma (TNBC) is one of the most aggressive subtypes of breast cancer and is associated with an unfavorable prognosis. The management of TNBC is currently based on the use of classical cytotoxic drugs, i.e., anthracyclines and/or microtubule‑binding agents (TBAs). However, conventional chemotherapy is not always effective in these tumors and a systemic relapse is often observed, potentially due to the development of multi‑drug resistance (MDR). Therefore, an improved understanding of MDR mechanisms may improve the therapeutic strategies for TNBC. In the present study, a paclitaxel‑resistant (TxR) breast cancer cell subline of HCC1806 TNBC cells was established and characterized. The resistance index of this subline was calculated according to the IC50 of HCC1806‑TxR relative to the parental HCC1806 cells (16.86‑fold). TxR‑cells also exhibited cross‑resistance to vinblastin, doxorubicin and etoposide (~14‑, ~4‑ and ~3‑fold, respectively). As assessed with reverse transcription‑quantitative polymerase chain reaction, TxR‑resistant cells exhibited the upregulated expression of a number of multidrug resistance‑associated genes, including MDR‑1, MRP‑1, ‑5, ‑6 and YB‑1. The TxR cells also exhibited an increased expression of MDR‑related proteins including MDR1 and MRP‑1, which led to a substantial increase (5.4‑fold) of the paclitaxel efflux from TxR‑cells. In addition, the pro‑apoptotic protein Fas was downregulated, whereas the anti‑apoptotic Bcl‑2 was upregulated, in TxR‑cells. This may explain why a reduced extent of apoptosis was observed when TxR cells were exposed to TBAs and topoisomerase type II inhibitors, relative to the parental HCC1806 cells. Thus, the HCC1806‑TxR cell line may serve as an appropriate model for the analysis of chemoresistance mechanisms in TNBCs, and for the investigation of novel anticancer agents for overcoming MDR‑mediated mechanisms in TNBC.

View Figures

View References

1	Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
2	Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, Fralick M, Kumar R and Clemons M: Survival outcomes for patients with metastatic triple-negative breast cancer: Implications for clinical practice and trial design. Clin Breast Cancer. 9:29–33. 2009. View Article : Google Scholar : PubMed/NCBI
3	Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004. View Article : Google Scholar : PubMed/NCBI
4	Dumontet C and Jordan MA: Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat Rev Drug Discov. 9:790–803. 2010. View Article : Google Scholar : PubMed/NCBI
5	Parker A, Kavallaris M and McCarroll JA: Microtubules and their role in cellular stress in cancer. Front Oncol. 4:1532014. View Article : Google Scholar : PubMed/NCBI
6	Bosch A, Eroles P, Zaragoza R, Viña JR and Lluch A: Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 36:206–215. 2010. View Article : Google Scholar : PubMed/NCBI
7	Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, et al: Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res. 19:2723–2733. 2013. View Article : Google Scholar : PubMed/NCBI
8	Ullah MF: Cancer multidrug resistance (MDR): A major impediment to effective chemotherapy. Asian Pac J Cancer Prev. 9:1–6. 2008.PubMed/NCBI
9	Hasanabady MH and Kalalinia F: ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer. J Biosci. 41:313–324. 2016. View Article : Google Scholar : PubMed/NCBI
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–428. 2001. View Article : Google Scholar : PubMed/NCBI
11	Ohga T, Uchiumi T, Makino Y, Koike K, Wada M, Kuwano M and Kohno K: Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem. 273:5997–6000. 1998. View Article : Google Scholar : PubMed/NCBI
12	Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 83:1797–1805. 1991. View Article : Google Scholar : PubMed/NCBI
13	Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J and Von Hoff D: A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol. 9:1261–1267. 1991. View Article : Google Scholar : PubMed/NCBI
14	McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK and Donehower RC: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 111:273–279. 1989. View Article : Google Scholar : PubMed/NCBI
15	Fuchs DA and Johnson RK: Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep. 62:1219–1222. 1978.PubMed/NCBI
16	Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature. 277:665–667. 1979. View Article : Google Scholar : PubMed/NCBI
17	Haldar S, Jena N and Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA. 92:4507–4511. 1995. View Article : Google Scholar : PubMed/NCBI
18	Weaver BA: How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
19	Guo B, Villeneuve DJ, Hembruff SL, Kirwan AF, Blais DE, Bonin M and Parissenti AM: Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat. 85:31–51. 2004. View Article : Google Scholar : PubMed/NCBI
20	McDonald SL, Stevenson DA, Moir SE, Hutcheon AW, Haites NE, Heys SD and Schofield AC: Genomic changes identified by comparative genomic hybridization in docetaxel-resistant breast cancer cell lines. Eur J Cancer. 41:1086–1094. 2005. View Article : Google Scholar : PubMed/NCBI
21	Sharom FJ: ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics. 9:105–127. 2008. View Article : Google Scholar : PubMed/NCBI
22	Kim KY, Kim SH, Yu SN, Park SK, Choi HD, Yu HS, Ji JH, Seo YK and Ahn SC: Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR human breast cancer cells via decreased efflux of doxorubicin. Mol Med Rep. 12:1898–1904. 2015. View Article : Google Scholar : PubMed/NCBI
23	Kröger N, Achterrath W, Hegewisch-Becker S, Mross K and Zander AR: Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev. 25:279–291. 1999. View Article : Google Scholar : PubMed/NCBI
24	Yonemori K, Katsumata N, Uno H, Matsumoto K, Kouno T, Tokunaga S, Yamanaka Y, Shimizu C, Ando M, Takeuchi M and Fujiwara Y: Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer. Breast Cancer Res Treat. 89:237–241. 2005. View Article : Google Scholar : PubMed/NCBI